Rhodes Pharmaceuticals, L.P.
11
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
91%
10 trials in Phase 3/4
50%
5 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
Role: lead
A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD
Role: lead
Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
Role: lead
Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD
Role: lead
The Efficacy and Safety of PRC-063 in Adult ADHD Patients
Role: lead
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
Role: lead
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
Role: lead
PRC-063 in an ADULT Workplace Environment
Role: lead
PRC-063 in Adolescent ADHD
Role: lead
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD
Role: lead
Safety and Efficacy of PG101 for Dry Eye Syndrome
Role: lead
All 11 trials loaded